Obesity White Papers & Case Studies

  1. The Renaissance Of Psychedelic Research: History, Protocols, And Forward Trajectories 7/30/2026

    Discover how clinical trial protocols are evolving to address unblinding, therapeutic support variables, and regulatory standards in modern psychedelic research.

  2. Full -Service NeuroScience CRO 7/29/2026

    Explore how dedicated brain and nervous system research support, deep disease expertise, and operational rigor can optimize your clinical trial's success.

  3. Everything You Need To Know About Vestigo®: Simplifying Investigational Drug Management 7/29/2026

    Streamline clinical trial pharmacy operations, slash manual documentation time, and maintain continuous audit readiness across complex studies.

  4. UK Clinical Trial Regulations Reform 7/24/2026

    UK trial regulations have been overhauled. Learn what faster approval pathways, stricter publication rules, and longer retention requirements mean for your operations.

  5. ICH E6(R3) Annex 2: Navigating GCP Requirements For Decentralized Trials 7/24/2026

    Implementing decentralized components or real-world data requires proactive alignment with updated GCP standards for data access, remote consent, and multi-stream investigator oversight.

  6. Five Preventable Clinical Design Pitfalls And How To Avoid Them 7/21/2026

    While late-stage trial attrition is often attributed to inadequate safety or efficacy, the true failure may be insufficient upstream planning and/or misalignment between clinical and commercial goals.

  7. Strategic Implications Of The Single Phase 3 Approval Paradigm 7/21/2026

    As FDA single-trial approvals gain traction, CNS developers need stronger early evidence. Learn how biomarkers, patient selection, and regulatory strategy can accelerate development.

  8. Busy Quarter For Gene, Cell, RNA Therapies 7/21/2026

    Explore how Q2 brought renewed momentum for gene, cell, and RNA therapies and grew confidence in the future of advanced medicine with rising approvals, expanding pipelines, and increased investment.

  9. Rapid Expansion Of Peptide And Nanobody Drug Conjugates 7/21/2026

    Peptide and nanobody drug conjugates are gaining momentum, with 106 active programs identified globally. Learn more about the fast-evolving space for targeted drug delivery and competitive opportunities.

  10. The Starting Point For Trial Transparency 7/21/2026

    Clinical trial sponsors can make results easier to find, understand, and share. Examine how participants stay informed while reducing manual distribution, tracking, and multilingual access challenges.